Disseminated leishmaniasis was first described in 1986, and it has been mainly reported in Northeastern Brazil [3–7]. Disseminated leishmaniasis is characterized by the presence of a great number of pleomorphic cutaneous lesions spanning 2 or more noncontiguous areas of the patient’s body [3–5]. The patients typically report a single initial lesion, usually on the extremities, followed by dissemination that may involve the entire body, sometimes associated with fever and chills [4]. Although DL accounted for 0.2% of the total number of cases of cutaneous leishmaniosi (CL) in the early 1970s, in 2000 this figure rose to 1.9% [5], and between 1988 and 2008 its prevalence increased 3-fold and culminated in 2.4% of the total number of cases [8].

The pathogenesis of DL remains unclear; parasite species, host, and environmental factors may favor parasite dissemination. Disseminated leishmaniasis patients have higher frequency of negative skin test to Leishmania antigen [4] as well as poorer interferon-gamma and tumor necrosis factor-alpha responses than patients with CL [3–5, 9]. Therefore, decreased T-cell response has been hypothesized to play a major role in parasite dissemination, and abnormal chemokine production may be associated with this phenomenon. In the same way, different subpopulations of L (V) braziliensis have been associated with distinct clinical outcomes and caused distinct in vitro reactivity in peripheral blood mononuclear cells of ATL patients. These findings have suggested that certain strains in this complex L braziliensis subpopulations may constitute a major risk of DL [10].

This study describes a series of 18 cases of DL. The first case was diagnosed in 1987 during ongoing outpatient clinic-based surveillance conducted at the University Hospital, Ribeirao Preto Medical School, University of Sao Paulo, Brazil, where DL cases had not been reported before.

SUBJECTS AND METHODS

Data Collection

Patients were attended at the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, which is the main reference for the diagnosis and treatment of ATL in the Northeastern region of the state of Sao Paulo, Brazil.

Disseminated Leishmaniasis Diagnosis

Disseminated leishmaniasis was identified according to a case definition of 10 or more pleomorphic lesions located in 2 or more body parts [3–5]. Laboratorial analyses confirmed case patients by identifying amastigotes forms in skin biopsies or Leishmania species in biopsy specimens with molecular methods. Patients with DL were identified between June 1987 and March 2015, by review of the medical charts of all the patients.
who received a diagnosis of ATL. A standardized entry form was used to extract the demographic, clinical, diagnostic, laboratory, and treatment information from the medical records.

**Leishmania Skin Test**

Leishmania skin test (LST) was performed as described previously [11], and induration equal to or higher than 5 mm, between 48 and 72 hours after the injection, was considered a positive result.

**Skin Biopsies**

The diagnosis was defined as leishmaniasis if the parasites were identified on the hematoxylin-eosin or Giemsa-stained sections. Leishmania species was determined in smears and/or skin biopsy samples. DNA was extracted from 5 paraffin-embedded skin samples and from 12 cryopreserved skin samples. There was no sample for one of the patients, who was the oldest case, diagnosed in 1987.

**Polymerase Chain Reaction**

The used primers were based on a sequence of the minicircle kDNA of Leishmania sp 5'-G(G)/C(G)/C(C)/A(C)CTAT (A/T)TTACACCCACCC-3' and 5'-GGGGAGGGCGTT CTGCGAA-3' (Eurofins, MWG Operon, Huntsville, AL) as described previously [2]. The reactions were performed in a Mastercycler Pro Thermocycler (Eppendorf, Hamburg, Germany) at the final volume of 23 µL, containing 12.9 µL distilled water, 2 µL 10x buffer (10 µM Tris-HCl [pH 8.6], 50 µM KCl, and 15 µM MgCl₂), 2.5 µL dNTPs (2 mM), 0.2 µL of each primer (40 µM), 0.2 µL Taq DNA polymerase (5 U/µL) (Invitrogen, Sao Paulo, Brazil), and 5 µL DNA extract. The amplification cycles included an initial denaturation step of 3 minutes and 30 seconds at 94°C, followed by 35 cycles at 94°C (30 seconds), 60°C (1 minute), 72°C (1 minute), a final extension at 72°C (10 minutes), and incubation at 4°C.

**Polymerase Chain Reaction Product Digestion and Leishmania Species Identification**

After amplification, HaeIII and BsrI enzymes (New England Biolabs Inc., Hitchin, England) were used to identify the Leishmania species by using the following reaction conditions: 37°C C and 1 µL HaeIII enzyme, 2 µL buffer solution, and 12 µL distilled water, and 5 µL polymerase chain reaction (PCR) product; 65°C and 1 µL BsrI enzyme, 2 µL buffer solution, and 12 µL distilled water, and 5 µL PCR product.

**Ethical Approval**

Informed consent was obtained from all the patients. This report was approved by the Local Human Ethics Committee (number 3605/2006) of the University Hospital of the Ribeirão Preto Medical School, University of Sao Paulo, Brazil, in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association.

**RESULTS**

A series of 18 patients—5.4% of ATL patients—with clinically and laboratory-confirmed DL were identified between June 1987 and March 2015 (Table 1).

**Demographic, Epidemiological, and Comorbidities Data**

The median age of the patients was 45 years old; the youngest patient was 24 years old, whereas the oldest patient was 75 years old. Seventeen patients were male. Most of the patients were agriculturists (33.3%). No municipalities or farm villages were identified more frequently; however, Pardo River (Sao Paulo state) and Paracatu River (Minas Gerais state) were common places amongst the patients with fishing habit. Twelve patients were smokers; 8 patients were alcoholics. Five patients had diabetes mellitus type 2; just 1 patient had human immunodeficiency virus (HIV) positive serology (no acquired immune deficiency syndrome condition).

**Clinical Characteristics**

The median evolution time was 6 months (minimum, 1 month; maximum, 48 months). An isolated ulcer was the initial clinical manifestation in most cases (55.5%); it emerged mainly in the face and lower extremities (Figure 1). Seven (38.8%) patients had concomitant mucosal involvement; nasal mucosa and/or septum were affected in 4 of these 7 patients, and the same proportion of patients (4 of 7) had oral lesions covering the hard palate.

**Laboratorial Results**

Ten (58.8%) of the 17 patients tested positive for LST. The median induration size was 8 mm (minimum, 5 mm; maximum, 14 mm). Leishmania skin test had not been registered in the medical chart of 1 patient. The biopsy sections showed infiltration with plasma cells and granulomatous reaction. Amastigotes were identified in 11 (61.1%) skin histological sections. DNA from 17 skin biopsies samples was analyzed by PCR. Amplified Leishmania sp was determined for 17 of these samples, which was followed by enzyme digestion to recognize the subgenus Viannia.

**Treatment Results**

Fifteen patients were treated initially with pentavalent antimony (Sb⁵⁺; 20 mg/kg per day) for 30 days (1 cycle), and 3 patients were treated with amphotericin B. Patients were evaluated 30 to 60 days after they finished treatment. When they were considered not cured, retreatment was done. Two cycles were necessary to obtain cure for 8 patients. For another one, 3 cycles were necessary. Among patients treated with pentavalent antimony: 1 of them presented secondary effects, and therapy was switched to amphotericin B; and 2 patients died, 1 due a renal acute tubular necrosis and the other due hospital pneumonia. Among the patients treated with amphotericin B (with final doses of 2.5–3.0 g): 1 patient presented impaired liver function, and amphotericin B was switched to pentavalent antimonial;
| State | Gender | Age at Onset (Years) | Year of Diagnosis | Occupation | Evolution Time (Months) | Origin at Diagnosis | LST | Mucosal Involvement | Amastigotes in Skin Samples | PCR | Leishmania Subgenus | Initial Treatment/ Follow Up |
|-------|--------|----------------------|-------------------|------------|------------------------|--------------------|-----|-------------------|----------------------------|-----|-------------------|----------------------------|
| SP    | M      | 24                   | 1987              | Hiker      | 48                     | Ribeirao Preto City | Positive | No                | Present                   | No sample | No sample | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 49                   | 1988              | Agriculturist | 3                     | Pardo River        | Negative | No                | Present                   | + (P) | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M*     | 56                   | 1988              | Agriculturist | 3                     | Santa Cruz da Esperança City | Positive | No                | Present                   | + (P) | Leishmania viannia | Glucantime<sup>1</sup>/Cure |
| MG    | F      | 33                   | 1991              | Agriculturist | 6                     | Santa Maria de Itabira City | Positive | Oral              | Present                   | + (P) | Leishmania viannia | Amphotericin-B<sup>2</sup>/Death |
| MG    | M      | 50                   | 1995              | Agriculturist | 18                    | Paracatu River     | Positive | No                | Present                   | +     | Leishmania viannia | Glucantime<sup>1</sup>/Death |
| MG    | M*     | 49                   | 1998              | Bricklayer  | 1                     | Paracatu River     | Negative | No                | Present                   | +     | Leishmania viannia | Glucantime<sup>2</sup>/Death |
| SP    | M      | 37                   | 1999              | Driver      | 1                     | Ribeirao Preto City | Not registered | Nasal          | Present                   | + (P) | Leishmania viannia | Amphotericin-B/Death          |
| SP    | M*     | 75                   | 2000              | Agriculturist | 8                     | Guatapara City     | Negative | Nasal and oral | Present                   | + (P) | Leishmania viannia | Glucantime<sup>2</sup>/Death |
| MG    | M      | 47                   | 2001              | Welder      | 2                     | Paracatu River     | Positive | No                | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M*     | 40                   | 2002              | Manager Fruit Market | 3                     | Ribeirao Preto City | Negative | No                | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M*     | 39                   | 2008              | Bricklayer  | 6                     | Espiritu Santo do Pinhal City | Positive | Oral              | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 43                   | 2009              | Bricklayer  | 8                     | Pardo River        | Positive | Oral              | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 67                   | 2010              | Traveling Salesman | 12                    | Jurucê City       | Positive | Nasal            | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 38                   | 2010              | Agriculturist | 8                     | Santa Ernestina City | Positive | No                | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 37                   | 2013              | Driver      | 6                     | Pardo River        | Negative | No                | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 58                   | 2014              | Bar Owner    | 6                     | Pardo River        | Negative | No                | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 43                   | 2014              | Machine Operator | 2                    | Pardo River        | Positive | Oral              | Absent                    | +     | Leishmania viannia | Glucantime<sup>2</sup>/Cure |
| SP    | M      | 58                   | 2015              | Electrician  | 7                     | Pardo River        | Negative | No                | Present                   | +     | Leishmania viannia | Amphotericin-B/Control         |

Abbreviations: HIV, human immunodeficiency virus; LST, Leishmania skin test; MG, Minas Gerais; (P), paraffin-embedded tissue; PCR, polymerase chain reaction; SP, Sao Paulo.

* Patient with diabetes mellitus type 2.
*<sup>2</sup> Switched to glucantime<sup>2</sup> due impairment liver function.
*<sup>3</sup> Patient with HIV positive serology.
*<sup>4</sup> Patient with chronic pulmonary obstructive disease.
*<sup>5</sup> Switched to amphotericin B due phlebitis and tremors.
<sup>1,2,3</sup> Number of cycles of 30 consecutive days with interval of 30 to 60 days prescribed to be cured.
and another one suffered hospital pneumonia (HIV-positive patient), followed by septic shock, and subsequently died.

**DISCUSSION**

The expansion of urban boundaries is accompanied by appearance of diseases that had been previously restricted to rural areas. Southeastern Brazil is not the exception; population growth associated with the constant increase in the agricultural market in these regions have resulted in urban invasion of forest regions [12]. This scenario presents a new stage of cohabitation with local fauna that was previously confined outside the cities. Nonetheless, outdoor work (such as agriculturist and bricklayer) and outdoor activities (such as fishing) seem to place people at higher risk of acquiring DL due to greater exposure to the *Leishmania*-transmitting mosquito [5].

Surveillance conducted in the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, between 1987 and 2015 showed a total of 335 patients with ATL. The localized cutaneous form corresponded to 70.4% (236 of 335) of the patients (data not published). Disseminated leishmaniasis was diagnosed in 5.4% of ATL cases. The latter percentage represents an important proportion compared with other reported series in which DL corresponded to 2.4% of CL cases [8]. Although ATL is endemic in Southeastern Brazil, the series of cases reported herein show a considerable number of DL cases. These cases must be monitored and evaluated as a new emerging clinical form of ATL in this region. It is of interest to note that the first DL case in our clinically diagnosed cases was diagnosed in 1987, whereas the first DL case reported in Brazil dates back to 1986 [3].

According to Turetz et al [5], old age is a risk factor for DL development—these authors established an odds ratio of 2.57 (95% confidence interval [CI], 1.25–5.70) for age over 20 years old. This information is consistent with the age range described in our study (24–75 years old); however, no difference was found when age was categorized in <20 years old, and ≥20 years old comparing DL to total ATL cases (*P* = .334); in fact, there is no DL patient under 20 years old.

In the present report, DL was more frequently diagnosed among male patients (17 of 18 were males). Our DL cases tend to be more frequently diagnosed in males compared with our total ATL cases, but no significant difference was found (odds ratio [OR] = 6.2; 95% CI, 0.82–47.8; *P* = .06). Nevertheless, in a larger series, male gender has been considered as

---

![Figure 1. Disseminated leishmaniasis caused by *Leishmania viannia* subgenus. Concomitant mucosal involvement (A) was found in 7 patients. In most cases, an isolated or coalescent ulcers (B), characteristic leishmaniotic, or uncharacteristic ulcer (C) antecede the spreading lesions to cephalic segment, mainly the face, trunk, and limbs, represented by a myriad of acneiform, nodular, or papular lesions, some of them superposed by crusts.](image-url)
a risk factor for DL (OR = 2.2; 95% CI, 1.03–5.31; P = .045) [5], and another study has also showed this tendency (12 males in 18 DL cases) [13].

Immune response in DL is able to control parasite growth, and only a few amastigotes remain in the lesion site. As a result of the local inflammatory response, the lesion becomes ulcerated later on [4]. It is of interest to note that 2 male patients who did not present the amastigote form in the skin biopsy and who tested negative for Leishmania sp by PCR analysis, but who fulfilled the clinical definition of DL, were excluded from this analysis. In these 2 cases, Leishmania sp etiologic involvement was supported by the epidemiological background, clinical manifestation, suggestive skin histopathological description for Leishmania infection (lymphoplasmacytic infiltrate with granuloma formation), and positive therapeutic response to N-methyl-gluconamine; however, they did not fulfill the inclusion criteria of this report, emphasizing the challenge in DL diagnosis.

In most of our cases, the initial clinical manifestation was the presence of an isolated ulcerated lesion with subsequent development of several cutaneous lesions, including a mixture of acneiform, nodular, and papular lesions as described previously [3, 5].

Seven (38.8%) patients presented simultaneous mucosal commitment and disseminated skin lesions. Mucosal lesions (MLs) are more frequent in DL patients compared with CL patients [5, 14]. Normally, MLs occur in 3% of patients with a history of CL and typically appear after several months or years after the initial cutaneous infection [1].

Pentavalent antimony was the preferred drug used to treat DL. Thirteen patients (81.2%) required 2 or 3 cycles of 30 consecutive days of antimonial treatment to be cured, although a high rate of therapeutic failure is described for DL [5]. In 1 case, amphotericin B was used with success, and the last diagnosed patient is still under medical control (less than 1-year follow up). Three deaths occurred in the casuistic: 1 was of them due to antimonial side effect (renal acute tubular necrosis), and the others 2 cases were due to pneumonia followed by sepsis or respiratory insufficiency.

In our casuistic, L viannia was identified as the subgenus in all DL cases. Considering the epidemiological profile in northeastern Sao Paulo state and the experience in our hospital, this subgenus highly suggests the L (V) braziliensis involvement; notwithstanding, further techniques should be performed to confirm the species. Influence of the parasite genotype on the clinical manifestation of the disease results from a cause-effect relationship. Single-nucleotide polymorphisms and indels associated with DL occur in 6 polymorphic loci in the parasite’s genome [10]. Reports on ATL clusters in Northeastern Brazil support the idea that the clinical manifestation of DL is related with a particular strain of the parasite [7, 10, 15]. The genetic background of the Leishmania parasite reported here should be determined for the detection of strains.

CONCLUSIONS

The present case series has reported on a detailed epidemiological, clinical, and laboratorial profile of an emerging form of ATL. Considering the alarming growing incidence of DL cases, clinicians must be aware of this emerging form of ATL. The challenges in this field include the difficulty to perform differential diagnosis amongst neglected dermatosis and to manage the disease.

Acknowledgments

We thank the clinical and laboratorial staff for helpful comments and suggestions during the preparation of the manuscript. We also thank Fundação de Amparo ao Ensino, Pesquisa e Assistencia (FAEPA), University Hospital of Ribeirao Preto, Ribeirao Preto Medical School, University of Sao Paulo, Brazil for partial financial support.

Financial support. This study was funded in part by FAEPA. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010; 949: xii–xiii, 1–86, back cover.
2. Medeiros AR, Silva WA, Roselino AM. DNA sequencing confirms the involvement of Leishmania (L.) amazonensis in American tegumentary leishmaniasis in the state of Sao Paulo, Brazil. Clinics (Sao Paulo) 2008; 63:451–6.
3. Costa JM, Marsden PD, Llanos-Cuentas EA, et al. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg 1986; 89:319–23.
4. Carvalho EM, Barral A, Costa JM, et al. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 1994; 56:315–25.
5. Turetz ML, Machado PR, Ko AI, et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 2002; 186:1829–34.
6. Galvão CE, Silva AC, Saldana AC, et al. [Disseminated cutaneous leishmaniasis due to Leishmania Viannia braziliensis in the state of Maranhão, Brazil]. Rev Soc Bras Med Trop 1993; 26:121–3.
7. Schriefer A, Guimarães LH, Machado PR, et al. Geographic clustering of leishmaniasis in northeastern Brazil. Emerg Infect Dis 2009; 15:871–6.
8. Jirmanus L, Glesby MJ, Guimarães LH, et al. Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg 2012; 86:426–33.
9. Vierra-Gonçalves R, Fittipaldi D, Jorge ME, et al. Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro. Int J Dermatol 2008; 47:926–32.
10. Queiroz A, Sousa R, Heine C, et al. Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol 2012; 50:4028–34.
11. Gomes CM, Paula NA, Morais OO, et al. Complementary exams in the diagnosis of American tegumentary leishmaniasis. An Bras Dermatol 2014; 89:701–9.
12. Tolezano JE. Ecoclinical aspects of American cutaneous leishmaniasis in the state of Sao Paulo, Brazil. Mem Inst Oswaldo Cruz 1994; 89:427–34.
13. Mendes DS, Dantas ML, Gomes JM, et al. Inflammation in disseminated leishmaniasis: an analysis of CD4+, CD20+, CD68+, CD31+ and vWf+ cells in non-ulcerated lesions of disseminated leishmaniasis. Mem Inst Oswaldo Cruz 2013; 108:18–22.
14. Machado PR, Rosa ME, Costa D, et al. Reappraisal of the immunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response. Trans R Soc Trop Med Hyg 2011; 105:438–44.
15. Schriefer A, Schriefer AL, Goes-Neto A, et al. Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemcity for American tegumentary leishmaniasis. Infect Immun 2004; 72:508–14.